Skip to main content
SpringerLink
Log in

TESSEE – Tool for Early Stem Cells Economic Evaluation

  • Conference paper
  • First Online:
XV Mediterranean Conference on Medical and Biological Engineering and Computing – MEDICON 2019 (MEDICON 2019)

Part of the book series: IFMBE Proceedings ((IFMBE,volume 76))

Abstract

Stem cell therapies are promising for diverse indications. However, there are manufacturing and reimbursement challenges that must be addressed toward widespread adoption. Relying on bioprocess and/or health economics models, early health technology assessment (eHTA) has provided insights on manufacturing innovations towards reducing the manufacturing cost of goods (CoG), and the long-term value that prospective stem cell therapies must provide to secure reimbursement. These economics models have focused on commercial tools or proprietary code. In order to increase awareness to the usefulness of eHTA in stem cell engineering, this thesis presents a new open-source tool, TESSEE (Tool for Early Stem Cells Economic Evaluation). Three relevant case studies for mesenchymal stem/stromal cell (MSC) and pluripotent stem cell (PSC) based therapies are presented as applications of TESSEE for decision-making in the implementation of stem cell engineering innovations. A study on the choice of a culture media supplement for autologous MSC therapy manufacturing determined that human platelet lysate (hPL) reduces CoG, in comparison to fetal bovine serum (FBS), for 97% of donors. An expansion system focused case study showed that the implementation of a new vertical wheel reactor (VWR) for the microcarrier-based culture of MSC increases the number of cells per batch and reduces costs of goods per dose by up to 48% from typical two-dimensional flasks for expansion. eHTA of devices containing PSC-derived beta cells for treatment of type 1 diabetes patients showed that the transplantation of the devices could be very effective at improving the quality of life. However, a price reduction, accompanied by reduction of manufacturing costs, is required to achieve widespread cost-effectiveness. This thesis highlights the versatility of TESSEE and builds evidence for eHTA for rational implementation of innovations in stem cell engineering, towards more cost-effective stem cell therapies.

Research supported by Fundação para a Ciência e Tecnologia (FCT) through the PhD Fellowship PD/BD/105868/2014.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Shukla, V., Seoane-Vazquez, E., Fawaz, S., Brown, L.M., Rodriguez-Monguio, R.: The landscape of cellular and gene therapy products: cost, approvals, and discontinuations. Hum. Gene Ther. Clin. Dev., April 2019. humc.2018.201

    Google Scholar 

  2. Home - ClinicalTrials.gov. https://clinicaltrials.gov/. Accessed 03 Jul 2019

  3. Simaria, A.S., et al.: Allogeneic cell therapy bioprocess economics and optimization: single-use cell expansion technologies. Biotechnol. Bioeng. 111(1), 69–83 (2014)

    Article  Google Scholar 

  4. Ikebe, C., Suzuki, K.: Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols. Biomed. Res. Int. 2014, 951512 (2014)

    Article  Google Scholar 

  5. Mizukami, A., et al.: Technologies for large-scale umbilical cord-derived MSC expansion: experimental performance and cost of goods analysis. Biochem. Eng. J. 135, 36–48 (2018)

    Article  Google Scholar 

  6. Banta, D.: The development of health technology assessment. Health Policy 63(2), 121–132 (2003)

    Article  Google Scholar 

  7. Ijzerman, M., Wissing, T., de Koning, E.: Early health economic evaluation of bioartificial organs: involving users in the design of the bioartificial pancreas for diabetes. In: Stamatialis, D. (ed.) Biomedical Membranes and (Bio)artificial Organs. World Scientific Publishing Co. Pte Ltd., New Jersey (2017)

    Google Scholar 

  8. de Windt, T.S., Sorel, J.C., Vonk, L.A., Kip, M.M.A., Ijzerman, M.J., Saris, D.B.F.: Early health economic modelling of single-stage cartilage repair. Guiding implementation of technologies in regenerative medicine. J. Tissue Eng. Regen. Med. 11(10), 2950–2959 (2017)

    Article  Google Scholar 

  9. Wallner, K., et al.: Stem cells and beta cell replacement therapy: a prospective health technology assessment study. BMC Endocr. Disord. 18(1), 6 (2018)

    Article  Google Scholar 

  10. Jenkins, M., Bilsland, J., Allsopp, T.E., Ho, S.V., Farid, S.S.: Patient-specific hiPSC bioprocessing for drug screening: bioprocess economics and optimisation. Biochem. Eng. J. 108, 84–97 (2016)

    Article  Google Scholar 

  11. Weil, B.D., et al.: An integrated experimental and economic evaluation of cell therapy affinity purification technologies. Regen. Med. 12(4), 397–417 (2017)

    Article  Google Scholar 

  12. Pereira Chilima, T.D., Moncaubeig, F., Farid, S.S.: Impact of allogeneic stem cell manufacturing decisions on cost of goods, process robustness and reimbursement. Biochem. Eng. J. 137, 132–151 (2018)

    Article  Google Scholar 

  13. Hassan, S., Simaria, A.S., Varadaraju, H., Gupta, S., Warren, K., Farid, S.S.: Allogeneic cell therapy bioprocess economics and optimization: downstream processing decisions. Regen. Med. 10(5), 591–609 (2015)

    Article  Google Scholar 

  14. Harrison, R.P., Medcalf, N., Rafiq, Q.A.: Cell therapy-processing economics: small-scale microfactories as a stepping stone toward large-scale macrofactories. Regen. Med. 13(2), 159–173 (2018)

    Article  Google Scholar 

  15. Darkins, C.L., Mandenius, C.-F.: Design of large-scale manufacturing of induced pluripotent stem cell derived cardiomyocytes. Chem. Eng. Res. Des. 92(6), 1142–1152 (2014)

    Article  Google Scholar 

  16. Placzek, M.R., et al.: Stem cell bioprocessing: fundamentals and principles. J. R. Soc. Interface 6(32), 209–232 (2009)

    Article  Google Scholar 

  17. Sampson, C.J., et al.: Transparency in decision modelling: what, why, who and how? Pharmacoeconomics, pp. 1–15, June 2019

    Google Scholar 

  18. TESSEE - Tool for Early Stem cellS Economic Evaluation Source Code. https://github.com/catiabandeiras/TESSEE. Accessed 10 Jul 2019

  19. Bandeiras, C., Cabral, J.M., Finkelstein, S.N., Ferreira, F.C.: Modeling biological and economic uncertainty on cell therapy manufacturing: the choice of culture media supplementation. Regen. Med. 13(8), 917–933 (2018)

    Article  Google Scholar 

  20. Sousa Pinto, D., et al.: Scalable manufacturing of human mesenchymal stromal cells in the vertical-WheelTM bioreactor system: an experimental and economic approach. Biotechnol. J., p. 1800716, April 2019

    Article  Google Scholar 

  21. Bandeiras, C., Cabral, J.M.S., Gabbay, R.A., Finkelstein, S.N., Ferreira, F.C.: Bringing stem cell-based therapies for type 1 diabetes to the clinic: early insights from bioprocess economics and cost-effectiveness analysis. Biotechnol. J., p. 1800563, May 2019

    Article  Google Scholar 

  22. Faulkner, S., et al.: Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways. Clin. Pharmacol. Ther. 100(6), 730–742 (2016)

    Article  Google Scholar 

  23. Sutton, M.T., et al.: Antimicrobial properties of mesenchymal stem cells: therapeutic potential for cystic fibrosis infection, and treatment. Stem Cells Int. 2016, 1–12 (2016)

    Article  Google Scholar 

  24. Bandeiras, C., Koc, J.R., Ma, Y., Samberg, M., Finkelstein, S., Ferreira, F.: Cost effectiveness analysis of allogeneic, just-in-time expansion of mesenchymal stem cells with PLUSTM human platelet lysate for a clinical trial. Cytotherapy 20(5), S60 (2018)

    Article  Google Scholar 

  25. Bandeiras, C., Cabral, J.M.S., Finkelstein, S.N., Ferreira, F.C.: Logical process designs for stem cell manufacturing: computational support tools for improved cost-effectiveness. RegMedNet (2017). https://www.regmednet.com/users/3641-regmednet/posts/19843-logical-process-designs-for-stem-cell-manufacturing-computational-support-tools-for-improved-cost-effectiveness

  26. ICER - Institute for Clinical and Economic Review. https://icer-review.org/. Accessed 10 Jul 2019

  27. Innovation and Value Initiative. https://www.thevalueinitiative.org/. Accessed 10 Jul 2019

Download references

Acknowledgment

The authors acknowledge funding from Institute for Bioengineering and Biosciences (UID/BIO/04565/2013) and Programa Operacional Regional de Lisboa 2020 (Project No. 007317) and also through the project PRECISE (PAC-PRECISE-LISBOA-01-0145-FEDER-016394). C. Bandeiras also acknowledges the support from the MIT Portugal Program in Bioengineering, namely through the research stays in the Institute for Data, System and Society – MIT and the Division of Clinical Informatics, Beth Israel Deaconess Medical Center, Harvard Medical School.

Author information

Authors and Affiliations

  1. Institute of Bioengineering and Biosciences, Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal

    Cátia Bandeiras, Joaquim Manuel Sampaio Cabral & Frederico Castelo Ferreira

  2. Institute for Data, Systems and Society, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA

    Stan Neil Finkelstein

Authors
  1. Cátia Bandeiras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joaquim Manuel Sampaio Cabral
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stan Neil Finkelstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Frederico Castelo Ferreira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cátia Bandeiras .

Editor information

Editors and Affiliations

  1. University of Coimbra, Coimbra, Portugal

    Jorge Henriques

  2. Universidade do Minho, Braga, Portugal

    Nuno Neves

  3. University of Coimbra, Coimbra, Portugal

    Paulo de Carvalho

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this paper

Check for updates. Verify currency and authenticity via CrossMark

Cite this paper

Bandeiras, C., Sampaio Cabral, J.M., Finkelstein, S.N., Ferreira, F.C. (2020). TESSEE – Tool for Early Stem Cells Economic Evaluation. In: Henriques, J., Neves, N., de Carvalho, P. (eds) XV Mediterranean Conference on Medical and Biological Engineering and Computing – MEDICON 2019. MEDICON 2019. IFMBE Proceedings, vol 76. Springer, Cham. https://doi.org/10.1007/978-3-030-31635-8_233

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-31635-8_233

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-31634-1

  • Online ISBN: 978-3-030-31635-8

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics

Search

Navigation